Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim vs Sargramostim Priming for Autologous Transplantation in Multiple Myeloma
NCT00005987Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2000
- Primary completion
- Jul 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of filgrastim, sargramostim in multiple myeloma (MM), sponsored by Masonic Cancer Center. Started Aug 2000; status: terminated.
02
Drugs
filgrastimsargramostim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00005987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005987.